A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
Status:
Not yet recruiting
Trial end date:
2023-12-12
Target enrollment:
Participant gender:
Summary
This is a one-arm phase II clinical study. In patients with stage III-IVA cervical cancer
with pelvic lymph nodes > 2cm, positive para-aortic lymph nodes, or lymph node metastases >
2, patients with positive PD-L1 expression (CPS score ≥1) were treated with cararizumab
combined with conventional concurrent chemoradiotherapy and immunomaintenance therapy for one
year. To evaluate the efficacy and safety of carilizumab in combination with concurrent
chemoradiotherapy and subsequent maintenance therapy.